Have questions? Contact Us
During this June ACIP Meeting the sincere appreciation was palpable in the room occupied by those focused on reviewing evidentiary support of RSV prevention solutions. “Astounding”, phenomenal”, “unbelievable” & “fantastic” are remarks heard at the conclusion of Dr. Payne’s presentation. Watch the nirsevimab real world data being covered from the 23-24 RSV season on day 3 of the ACIP meeting.
Since Respiratory Syncytial Virus (RSV) is well known for being the number one cause of infant hospitalization in the United States, this post licensure data on nirsevimab-alip, trade name Beyfortus™ is welcome news. Moreover, BEYFORTUS™ nirsevimab-alip supply should be more readily available this 2nd RSV season since FDA approval.
Healthcare professionals interested in Beyfortus™ may find the link to recommendations here. Additionally, as the RSV season approaches, physicians may access preferred pricing on BEYFORTUS™(nirsevimab-alip) through a PracticeWell Physician Buying Group ( PBG ) membership and purchased directly through the manufacturer. Sanofi at VaccineShop.com.